TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06114121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block (ESP)
Description: nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duramorph
Description: 100 micrograms (mcg) of morphine administered in the spinal medications one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duramorph
Description: 100 micrograms (mcg) of morphine administered in the spinal medications one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time.
Study: NCT06147843

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample will be taken to identify Genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss
Study: NCT05955612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procalcitonin measurement
Description: Daily measurement of serum procalcitonin concentrations to guide de-escalation of antibiotics
Study: NCT06523985

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Push messages (standard)
Description: Push messages will be developed based on best practice recruitment principles in cooperation with an external marketing team and then reviewed and finalized by the study team. Messages will be different each month and sent across 12 months. The monthly time frame was selected based on our need to balance contact with responders and research or expert opinions on push messaging saturation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push messages (customized)
Description: These messages are similar to content in the standard push messages but are customized to address common misperceptions about opioid overdose and naloxone.
Study: NCT05830864

Intervention type: DRUG
Intervention: Isoflurane
Description: no other intervention
Study: NCT05686239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RL-007
Description: investigational study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RL-007
Description: investigational study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules matching the appearance and size of the active drug
Study: NCT05022550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEEP VR
Description: DEEP VR is a virtual reality experience (i.e., video game using a head-mounted display) wherein participants ('players') traverse through a serene underwater adventure for approximately 15 min. Movement through the environment is facilitates through the cued use of regularized, diaphragmatic breathing, captured through a respiratory belt.
Study: NCT06353997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Drug will be delivered per standard-of-care as established by trial Keynote-522.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106
Description: INBRX-106 is a hexavalent, recombinant humanized IgG1, OX40 agonist antibody that targets the human OX40 receptor (TNFRSF4, UniProtKB: P43489). INBRX-106 is based on a sdAb platform and, in detail, 3 identical humanized camelid heavy chain-only antibody binding domains (VHHs) targeting OX40 are joined end-to-end and with an Fc based on human IgG1 to create a molecule that homo-dimerizes into an antibody targeting a total of 6 OX40 receptors.
Study: NCT06204679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions
Description: A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions
Description: A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions
Description: Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations
Study: NCT06490809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Parkinson\&#39;s upper extremity rehabilitation generally consists of stretching, strengthening, coordination, recreational activities and skill activities. Exercises will be prescribed by the clinical specialist physician and physiotherapist.
Study: NCT05580523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid
Description: 75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid
Description: 75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5g Metformin
Description: up to 1.5 g metformin (C4H11N5, CAS number 657-24-9) daily, Oral Dose increases from 0.5g to 1.0g to 1.5g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg acetylsalicylic acid
Description: 150 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of acetylsalicylic acid and Metformin
Description: Pills with shape, color and smell same with acetylsalicylic acid and metformin, daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of acetylsalicylic acid and Metformin
Description: Pills with shape, color and smell same with acetylsalicylic acid and metformin, daily, oral
Study: NCT01028443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmune

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artelose
Study: NCT06135961

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eCTG monitoring with the NFMS
Description: Device: Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands)
Study: NCT05500287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Care
Description: Children in the virtual care group had distance asthma education, case management and virtual care
Study: NCT04984031

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA assessment of apoptosis markers in gingival crevicular fluid
Description: Gingival crevicular fluid (GCF) samples will be collected to assess the level of caspase-3,8,9 and apoptosis inducing factor (Aif)

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA assessment of apoptosis markers in gingival crevicular fluid
Description: Gingival crevicular fluid (GCF) samples will be collected to assess the level of caspase-3,8,9 and apoptosis inducing factor (Aif)
Study: NCT04337580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg twice daily
Description: Participants will be treated with omeprazole 80 mg twice daily on Day 0. Within 10 days of starting omeprazole, participants will be treated with standard prostate cancer dosing of every three week docetaxel or cabazitaxel based on package insert. Participants that have only had docetaxel will be retreated with docetaxel along with concurrent omeprazole. Patients that have had both docetaxel and cabazitaxel will be retreated with either cabazitaxel or docetaxel (investigators choice) along with concurrent omeprazole. However investigators encourage investigator to choose cabazitaxel in patients previously treated with cabazitaxel.
Study: NCT06579755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injection.
Study: NCT06211114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-(L)1 inhibitor
Description: Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: axitinib 5mg orally twice daily
Study: NCT05222958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gestob App
Description: Gestop App is a mobile app that aims to help pregnant women quit smoking through gamification. It also allows you to obtain information about tobacco and pregnancy.
Study: NCT05531786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
Study: NCT06538584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 10mg/kg
Description: Subjects will be randomized prior to surgery into one of two arms. One arm will receive 10mg/kg Caffeine citrate 15 minutes post surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Citrate
Description: Subjects will be randomized prior to surgery into one of two arms. One arm will receive 0.9% Sodium Citrate/kg 15 minutes post surgery.
Study: NCT04645147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV gp350-Ferritin Vaccine
Description: A 50 micrograms dose of EBV gp350-Ferritin vaccine will be administered intramuscularly for each vaccination at Days 0, 30, and 180 to all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M1
Description: Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1.
Study: NCT06133244

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging, blood samples, fuctional tests and physical examination
Description: Imaging, blood samples, fuctional tests and physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging, blood samples, fuctional tests and physical examination
Description: Imaging, blood samples, fuctional tests and physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging, blood samples, fuctional tests and physical examination
Description: Imaging, blood samples, fuctional tests and physical examination
Study: NCT04583280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir
Description: Participants of age group greater than or equal to (\>=) 28 days to less than (\<) 3 months (age group 1) or \>= 3 months to \< 6 months (age group 2) or \>= 6 months to less than or equal to (\<=) 5 years (age group 3) will receive rilematovir orally twice a day (BID) from Days 1 to Day 7 or Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir X mg/kg
Description: Participants of age group birth at term (after at least 37 weeks of gestation) to \< 28 days (age group 4) will receive rilematovir orally BID from Days 1 to Day 7 or Day 8. The dose is dependent on outcome of the substudy in neonates and following independent data monitoring (IDMC) review and recommendation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant of age group 1, 2, 3 and 4 will receive matching placebo of rilematovir BID from Days 1 to Day 7 or Day 8 as per assigned age group.
Study: NCT05472935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: Mindfulness Based Stress Reduction (MBSR) is an evidenced based intervention utilized to reduce stress.
Study: NCT05955898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents THRIVE
Description: Parents THRIVE is a digital, one-time intervention that will give parents strategies to cope with their emotions and improve their distress tolerance. Parents will learn how to increase their emotion awareness to better tolerate strong emotions, such as anxiety, sadness, anger, and frustration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sharing Feelings Project
Description: Sharing Feelings Project is a digital, one-time program that focuses on the benefit of sharing emotions with others and will be used as a control. Parents will read about how sharing their emotions can be helpful and anecdotes from others' experiences sharing emotions.
Study: NCT05130047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: 1 mg solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aldafermin placebo solution
Study: NCT03517475

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SHS Low-Income
Description: An intervention to train caregivers to supervise their children appropriately.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHS Low-Income
Description: An intervention to train caregivers to supervise their children appropriately.
Study: NCT05814185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periodontal distractor
Description: different activation protocols of periodontal distractor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periodontal distractor
Description: different activation protocols of periodontal distractor
Study: NCT06459375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified otago exercises
Description: patients will receive modified Otago exercises with conventional treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Observation Training
Description: Patients will receive Action Observation Training with conventional treatment.
Study: NCT05425602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01: 50mg/70mg
Description: \[Stage 1\]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. \[Stage 2\]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
Study: NCT05288309

Intervention type: OTHER
Group type: OTHER
Intervention: RAINSTİCK
Description: When the child, who was taken to Experimental Group 1, sat on the patient's chair, the sound of the rain stick was started to be played 1 minute before the blood draw. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flowed to the vacuum within 5 seconds, showing that the procedure was successful. This process took about 2-3 minutes and the children listened to the sound of rain sticks throughout the process.

Intervention type: OTHER
Group type: OTHER
Intervention: KALEİDOSCOPE
Description: The child, who was taken into Experimental Group 2, was started to watch the kaleidoscope 1 minute before the blood draw, as he sat on the patient's chair. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flow to the vacuum within 5 seconds showed that the procedure was successful. This process took about 2-3 minutes and children were watched with kaleidoscope throughout the process.
Study: NCT05030025

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abacavir, dolutegravir and lamivudine dispersible tablets
Description: Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abacavir, dolutegravir and lamivudine dispersible tablets
Description: Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine
Description: Triumeq Dispersible Tablets 5 mg GSK1349572 \[Dolutegravir\]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine
Description: Triumeq Dispersible Tablets 5 mg GSK1349572 \[Dolutegravir\]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
Study: NCT05926817

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-VR headsets
Description: Patients in the Placebo-VR group watched a 10-minute relaxation-based 2D film through VR headsets along with receiving conventional analgesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QTC-VR headsets
Description: Patients in the QTC-VR group engaged in 10-minute interactive pain relief 3D VR programs while wearing VR headsets along with receiving conventional analgesia.
Study: NCT05611671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (identical appearance to MORF-057) administered orally.
Study: NCT05918640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
Study: NCT06015828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin
Description: Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
Study: NCT04859322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Pancreatic clamp
Study: NCT05222581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes of breast shield and Freedom Double Electric Breast Pump
Description: Prototypes of breast shield and Freedom Double Electric Breast Pump.
Study: NCT04749940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
Description: Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
Study: NCT06427213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib,Obinutuzumab
Description: Zanubrutinib, 160mg PO BID. C1D17 continuously for 1 year or until progressive disease； Obinutuzumab ：Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks，up to 20 doses. 1 cycle = 28 days.~Maintenance: Zanubrutinib, 160mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib and R-BAC
Description: Induction: Zanubrutinib and R-BAC 6 cycles~Consolidation: ASCT（If eligible for transplantation），Otherwise, the patient was directly entered into maintenance treatment~Maintenance: Zanubrutinib continued until progression
Study: NCT05104853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-104
Description: CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-104
Description: CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CNP-104 Placebo
Study: NCT05607667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement system
Study: NCT04785222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
Description: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
Description: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
Description: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
Study: NCT05214534

Intervention type: OTHER
Intervention: blood supar measurement
Description: The supar values will be measured afterwards on the tube bottoms of the patients included in the study from their usual collection